Table S1. Summary of studies investigating the re-bleeding rate on a long-term basis.
| Author, year (ref) | Country | Study design | No. of patients with long-term follow-up data/enrolled study patients | No. of patients with positive index VCE | Most frequent lesion in index VCE | No. of patients with negative index VCE | Total recurrent bleeding (%) | Re-bleeding rate after positive VCE (%) | Re-bleeding rate after negative VCE (%) | Mean follow-up duration (months) |
|---|---|---|---|---|---|---|---|---|---|---|
| Delvaux et al. 2004 (17) | France | Retrospective, single center | 42/44 | 17 | Angiodysplasia | 25 | 1 (2.3) | 1 (5.9) | 0 (0.0) | 12 |
| Pennazio et al. 2004 (46) | Italy | Prospective, multi center | 91/100 | 40 | Angiodysplasia | 51 | 32 (35.1) | 8 (20.0) | 24 (47.0) | 18 |
| Neu et al. 2004 (18) | Germany | Prospective, multi center | 56/56 | 38 | Angiodysplasia | 18 | 21 (37.5) | 17 (44.7) | 4 (22.2) | 13 |
| Saurin et al. 2005 (38) | France | Prospective, single center | 56/58 | 40 | Angiodysplasia | 16 | 16 (28.5) | 12 (75.0) | 4 (25.0) | 12 |
| Estevez et al. 2005 (47) | Spain | Prospective, single center | 95/100 | 63 | Angiodysplasia | 32 | 68 (71.5) | 47 (69.1) | 21 (65.6) | 12 |
| Lai et al. 2006 (19) | China | Prospective, single center | 49/49 | 31 | Angiodysplasia | 18 | 16 (32.7) | 15 (48.4) | 1 (5.6) | 19 |
| Leighton et al. 2006 (54) | USA | Prospective, single center | 20/20 | 10 | Angiodysplasia | 10 | 7 (37) | NA | NA | 12 |
| Apostolopoulos et al. 2007 (48) | Greece | Prospective, single center | 32/37 | 29 | Angiodysplasia | 3 | 5 (15.6) | 3 (60.0) | 2 (40.0) | 12 |
| García-Compean et al. 2007 (49) | USA | Prospective, single center | 40/40 | 30 | Angiodysplasia | 10 | 7 (23.3) | 6 (20.0) | 1 (10.0) | 13 |
| Albert et al. 2008 (22) | Germany | Retrospective, multi center | 240/285 | 186 | Angiodysplasia | 54 | 65 (27.1) | 56 (30.1) | 9 (16.7) | 21 |
| Endo et al. 2008 (33) | Japan | Retrospective, single center | 77/77 | 45 | Ulcer | 32 | 28 (36.4) | 12 (26.7) | 16 (50.0) | 12 |
| Hindryckx et al. 2008 (39) | Belgium | Retrospective, single center | 92/99 | 55 | Angiodysplasia | 37 | 23 (25.0) | 16 (29.1) | 7 (18.9) | 21 |
| Macdonald et al. 2008 (21) | UK | Retrospective, single center | 42/49 | 24 | Angiodysplasia | 18 | 12 (28.0) | 10 (41.7) | 2 (11.1) | 17 |
| Redondo-Cerezo et al. (20)† | Spain | Prospective, single center | 30/30 | 30 | Angiodysplasia | NA | 5 (16.7) | 5 (16.7) | NA | 12 |
| Viazis et al. 2009 (23) | Greece | Prospective, single center | 279/293 | 118 | Angiodysplasia | 161 | 145 (52.0) | 41 (34.7) | 104 (64.6) | 25 |
| Esaki et al. 2010 (51) | Japan | Retrospective, single center | 68/76 | 36 | Angiodysplasia | 32 | 17 (53.1) | 8 (22.2) | 9 (28.1) | 15 |
| Laine et al. 2010 (24) | USA | Prospective, single center | 66/66 | 20 | NA | 46 | 20 (30.0) | 5 (25.0) | 15 (33.0) | 12 |
| Lorenceau-Savale et al. 2010 (40)‡ | France | Retrospective, single center | 35/49 | 65 | NA | 35 | 8 (22.8) | NA | 8 (22.8) | 15 |
| Park et al. 2010 (34) | S. Korea | Retrospective, single center | 51/57 | 23 | Angiodysplasia | 28 | 18 (35.3) | 8 (34.8) | 10 (35.7) | 32 |
| Canas-Ventura et al. 2013 (52) | Spain | Retrospective, single center | 105/108 | 61 | Angiodysplasia | 44 | 32 (30.8) | 8 (13.1) | 24 (54.5) | 12 |
| Kim et al. 2013 (35) | S. Korea | Retrospective, single center | 125/125 | 62 | NA | 63 | 28 (23.2) | 12 (19.4) | 16 (26.7) | 24 |
| Koh et al. 2013 (32) | S. Korea | Retrospective, single center | 95/95 | 38 | Angiodysplasia | 57§ | 27 (28.4) | 15 (39.4) | 12 (23.5) | 24 |
| Mussetto et al. 2013 (41) | Italy | Prospective, single center | 118/118 | 68 | Angiodysplasia | 50 | 15 (12.7) | 12 (17.6) | 3 (6.0) | 16 |
| Pongprasobchai et al. 2013 (36) | Thailand | Retrospective, single center | 103/106 | 37 | Ulcer | 66¶ | 11 (12.5) | 2 (5.4) | 9 (17.6) | NA |
| Riccioni et al. 2013 (25) | Italy | Retrospective, single center | 696/696 | 489 | NA | 207 | 255 (36.6) | 221 (45.2) | 34 (16.4) | 24 |
| Cúrdia Gonçalves et al.2014 (62)‡ | Portugal | Retrospective, single center | 68/79 | 177 | NA | 68 | 16 (23.5) | NA | 16 (23.5) | 32 |
| Katsinelos et al. 2014 (26) | Greece | Prospective multicenter | 118/118 | 79 | Angiodysplasia | 39 | 17 (14.4) | 16 (20.3) | 1 (2.6) | 13 |
| Matsumura et al. 2014 (63) | Japan | Retrospective, single center | 260/396 | 106 | Ulcer | 154 | 20 (7.0) | 7 (6.6) | 13 (8.4) | 45 |
| Min et al. 2014 (37) | S. Korea | Prospective multicenter | 305/357 | 157 | Ulcer | 148¥ | 58 (19.0) | 44 (28.0) | 14 (12.3) | 39 |
| Magaelhaes-Costa et al. 2015 (31)‡ | Portugal | Retrospective, single center | 113/640 | 527 | NA | 113 | 31 (27.4) | NA | 31 (27.4) | 48 |
| Ribeiro et al. 2015 (27) | Portugal | Retrospective, single center | 173/173 | 79 | Ulcer | 94 | 39 (22.5) | 24 (30.4) | 15 (16.0) | 27 |
| Tan et al. 2015 (28) | China | Retrospective, single center | 339/372 | 222 | Angiodysplasia | 117 | 97 (28.6) | 81 (36.5) | 16 (13.7) | 48 |
| Niikura et al. 2016 (29) | Japan | Retrospective, Multicenter | 320/320 | 92 | Ulcer | 228 | 43 (13.4) | 19 (20.7) | 24 (10.5) | 20 |
| Ormeci et al. 2016 (30) | Turkey | Retrospective single center | 139/141 | 118 | Angiodysplasia | 21 | 56 (40.3) | 55 (46.6) | 1 (4.8) | 32 |
†, the study analyzed only OGIB patients with positive index VCE examination; ‡, the study analyzed only OGIB patients with negative index VCE examination; §, in 6 of 57 patients, VCE identified suspicious or equivocal findings for OGIB: one of them (16.7%) experienced re-bleeding episode; ¶, in 15 of 66 patients, VCE identified suspicious or equivocal findings for OGIB; none of them (0%) experienced a re-bleeding episode; ¥, in 34 of 148 patients, VCE identified suspicious or equivocal findings for OGIB; none of them (0%) experienced a re-bleeding episode. NA, not applicable; VCE, video capsule endoscopy.